{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-2.5-pro",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "29c1914a-2a46-48ff-93d5-f36b18850476",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "9ed13744-a898-4502-b467-8cc491b3a389",
          "code": {
            "id": "71d4b077-86c8-4e1a-924b-ee929b9c8614",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "ff1b4cc4-6909-4fee-8285-d2a1a2502a78",
            "type": {
              "id": "95347bad-99b4-439a-b680-5903c26696b6",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Upon approval, some of the safety and efficacy assessments will be reduced due to: 1) completion of efficacy analyses including interim and final analysis of primary endpoint and secondary endpoints; 2) additional analyses of safety conducted to comply with Health Authorities requirements; 3) at the time of amendment approval a smaller number of patients will be on study treatment and patients will remain under observation for a follow-up period of approximately 1 year and a half.",
        "effectiveDate": "2015-10-20",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_2",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "6a9c49dc-403e-462b-8008-fef0390b1e2b",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "77f254ff-01be-43e4-9a07-a03aa740a03b",
          "code": {
            "id": "0dd2b551-225a-46e3-b06c-7a460bd8cd68",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "34004a4f-6466-4191-a2e6-3c30aa1be98d",
            "type": {
              "id": "2616d8bb-39ce-4429-a218-6d5687c5a948",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "This amendment added prospective monitoring of hemoglobin A1c to characterize effects on glucose metabolism, updated human pharmacokinetic data to support administration with food, prohibited concomitant use of proton-pump inhibitors and strong/moderate CYP3A inducers/inhibitors, and refined criteria for treatment restart after toxicity.",
        "effectiveDate": "2014-09-30",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2",
          "ar_2_3"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      },
      {
        "id": "amend_3",
        "number": "1",
        "name": "Amendment 1",
        "scope": {
          "id": "7bdd301d-cf9e-407f-9786-fd41e24e2a91",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "a82ccdb8-82c0-4db2-a537-c747e616f5ee",
          "code": {
            "id": "3dc28ac3-ff29-4d33-889d-04479e68ac18",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "691369e9-95a9-40a9-893d-7a17a1dec011",
            "type": {
              "id": "1db5331b-ad6a-4721-a04c-2ff6c3d9afc4",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "This amendment added ocular safety assessment procedures to assess the potential risk of palbociclib-associated lens changes, incorporated preliminary results from clinical pharmacology studies to recommend taking palbociclib with food and prohibit proton-pump inhibitors, and clarified inclusion/exclusion criteria to address frequent questions from investigational sites.",
        "effectiveDate": "2014-04-04",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2",
          "ar_3_3"
        ],
        "previousVersion": "Original protocol",
        "newVersion": "1"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 3,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "International",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "North America",
        "Europe"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "3",
        "effectiveDate": "2015-10-20",
        "summary": "Upon approval, some of the safety and efficacy assessments will be reduced due to: 1) completion of efficacy analyses including interim and final analysis of primary endpoint and secondary endpoints; 2) additional analyses of safety conducted to comply with Health Authorities requirements; 3) at the time of amendment approval a smaller number of patients will be on study treatment and patients will remain under observation for a follow-up period of approximately 1 year and a half.",
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": [
          "Operational",
          "Regulatory"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2014-09-30",
        "summary": "This amendment added prospective monitoring of hemoglobin A1c to characterize effects on glucose metabolism, updated human pharmacokinetic data to support administration with food, prohibited concomitant use of proton-pump inhibitors and strong/moderate CYP3A inducers/inhibitors, and refined criteria for treatment restart after toxicity.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Safety",
          "Operational",
          "Scientific"
        ]
      },
      {
        "number": "1",
        "effectiveDate": "2014-04-04",
        "summary": "This amendment added ocular safety assessment procedures to assess the potential risk of palbociclib-associated lens changes, incorporated preliminary results from clinical pharmacology studies to recommend taking palbociclib with food and prohibit proton-pump inhibitors, and clarified inclusion/exclusion criteria to address frequent questions from investigational sites.",
        "previousVersion": "Original protocol",
        "newVersion": "1",
        "reasons": [
          "Safety",
          "Operational",
          "Scientific"
        ]
      }
    ],
    "geographicScope": {
      "type": "International",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "North America",
        "Europe"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}